Jessica E Pritchard1, Lauren E Wilson1, Samuel M Miller2,3, Melissa A Greiner1, Harvey Jay Cohen4, Deborah R Kaye5, Tian Zhang6,7, Michaela A Dinan8,9. 1. Department of Population Health Sciences, Duke University, Durham, North Carolina, USA. 2. National Clinician Scholars Program, Yale University, New Haven, Connecticut, USA. 3. Department of Surgery, Yale University, New Haven, Connecticut, USA. 4. Center for the Study of Aging and Human Development, Duke University, Durham, North Carolina, USA. 5. Department of Surgery, Division of Urology, Duke University, Durham, North Carolina, USA. 6. Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA. 7. Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA. 8. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA. 9. Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut, USA.
Abstract
BACKGROUND: Kidney cancer is the fastest-growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five-year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and may have mild cognitive impairment or dementia (MCI/D). Given prior reports of patients with dementia initiating less cancer therapy and the importance of oral anticancer agents (OAAs) in mRCC treatment, we investigated the prevalence of preexisting MCI/D in patients with mRCC and their OAA use. METHODS: SEER-Medicare patients were analyzed who were ≥65 years, diagnosed with mRCC between 2007 and 2015, and had Medicare part D coverage. Patterns and predictors of (a) OAA utilization within the 12 months following mRCC diagnosis and (b) adherence (percent of days covered [PDC] ≥ 80%) during the first 90 days following treatment initiation were assessed. RESULTS: Of the 2792 eligible patients, 268 had preexisting MCI/D, and 907 initiated OAA treatment within 12 months of mRCC diagnosis. Patients with preexisting MCI/D were less likely to begin an OAA than those without MCI/D (fully-adjusted HR 0.53, 95% CI 0.38-0.76). Among OAA initiators, a preexisting MCI/D diagnosis did not alter the likelihood that a person would be adherent (adjusted RR 0.84, 95% CI 0.55-1.28). CONCLUSIONS: Patients with preexisting MCI/D were half as likely to start an OAA during the year following mRCC diagnosis than patients without comorbid MCI/D. The 90-day adherence of OAA initiators was not significantly different between those with and without preexisting MCI/D. In light of this, clinicians should assess mRCC patients for cognitive impairment and take steps to optimize OAA utilization by those with MCI/D.
BACKGROUND: Kidney cancer is the fastest-growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five-year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and may have mild cognitive impairment or dementia (MCI/D). Given prior reports of patients with dementia initiating less cancer therapy and the importance of oral anticancer agents (OAAs) in mRCC treatment, we investigated the prevalence of preexisting MCI/D in patients with mRCC and their OAA use. METHODS: SEER-Medicare patients were analyzed who were ≥65 years, diagnosed with mRCC between 2007 and 2015, and had Medicare part D coverage. Patterns and predictors of (a) OAA utilization within the 12 months following mRCC diagnosis and (b) adherence (percent of days covered [PDC] ≥ 80%) during the first 90 days following treatment initiation were assessed. RESULTS: Of the 2792 eligible patients, 268 had preexisting MCI/D, and 907 initiated OAA treatment within 12 months of mRCC diagnosis. Patients with preexisting MCI/D were less likely to begin an OAA than those without MCI/D (fully-adjusted HR 0.53, 95% CI 0.38-0.76). Among OAA initiators, a preexisting MCI/D diagnosis did not alter the likelihood that a person would be adherent (adjusted RR 0.84, 95% CI 0.55-1.28). CONCLUSIONS: Patients with preexisting MCI/D were half as likely to start an OAA during the year following mRCC diagnosis than patients without comorbid MCI/D. The 90-day adherence of OAA initiators was not significantly different between those with and without preexisting MCI/D. In light of this, clinicians should assess mRCC patients for cognitive impairment and take steps to optimize OAA utilization by those with MCI/D.
Authors: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908
Authors: Beth L Nordstrom; Joanna L Whyte; Marilyn Stolar; Catherine Mercaldi; Joel D Kallich Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Gretchen Kimmick; Steven T Fleming; Susan A Sabatino; Xiao-Cheng Wu; Wenke Hwang; J Frank Wilson; Mary Jo Lund; Rosemary Cress; Roger T Anderson Journal: J Am Geriatr Soc Date: 2014-02-10 Impact factor: 5.562
Authors: Marije E Hamaker; Marthe Te Molder; Noortje Thielen; Barbara C van Munster; Anandi H Schiphorst; Lieke H van Huis Journal: J Geriatr Oncol Date: 2018-04-07 Impact factor: 3.599
Authors: Lidia M V R Moura; Natalia Festa; Mary Price; Margarita Volya; Nicole M Benson; Sahar Zafar; Max Weiss; Deborah Blacker; Sharon-Lise Normand; Joseph P Newhouse; John Hsu Journal: J Am Geriatr Soc Date: 2021-04-26 Impact factor: 7.538
Authors: Jason Shafrin; Jeffrey Sullivan; Jacquelyn W Chou; Michael N Neely; Justin F Doan; J Ross Maclean Journal: Cancer Manag Res Date: 2017-11-29 Impact factor: 3.989